請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51804
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.author | Yao-Chun Wen | en |
dc.contributor.author | 溫燿駿 | zh_TW |
dc.date.accessioned | 2021-06-15T13:50:42Z | - |
dc.date.available | 2021-02-26 | |
dc.date.copyright | 2016-02-26 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-10-15 | |
dc.identifier.citation | 1. 民國102年死因統計年報. 2015. (Accessed July 14, 2015, at http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=46319&s=1.)
2. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. N Engl J Med 2010;362:2155-65. 3. Shanmugasegaram S, Dai S, Waters C. Incidence and Prevalence of Acute Myocardial Infarction in Canada. J Am Coll Cardiol 2015;65:A1385. 4. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation 2011;123:46-52. 5. Koopman C, Bots ML, van Oeffelen AA, et al. Population trends and inequalities in incidence and short-term outcome of acute myocardial infarction between 1998 and 2007. Int J Cardiol 2013;168:993-8. 6. Takii T, Yasuda S, Takahashi J, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI Registry Study. Circ J 2010;74:93-100. 7. Kojima S, Matsui K, Ogawa H. Temporal trends in hospitalization for acute myocardial infarction between 2004 and 2011 in Kumamoto, Japan. Circ J 2013;77:2841-3. 8. Lee CH, Cheng CL, Yang YH, et al. Trends in the incidence and management of acute myocardial infarction from 1999 to 2008: get with the guidelines performance measures in Taiwan. J Am Heart Assoc 2014;3. 9. Chiang C-H, Huang W-C, Yang J-S, et al. Five-Year Outcomes after Acute Myocardial Infarction in Patients with and without Diabetes Mellitus in Taiwan, 1996-2005. Acta Cardiologica Sinica 2013;29:387-94. 10. Yang HY, Huang JH, Hsu CY, Chen YJ. Gender differences and the trend in the acute myocardial infarction: a 10-year nationwide population-based analysis. ScientificWorldJournal 2012;2012:184075. 11. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008;29:932-40. 12. Nawrot TS, Perez L, Künzli N, Munters E, Nemery B. Public health importance of triggers of myocardial infarction: a comparative risk assessment. The Lancet 2011;377:732-40. 13. Lin ST, Chen CC, Tsang HY, et al. Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation 2014;130:235-43. 14. Brauer R, Smeeth L, Anaya-Izquierdo K, et al. Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J 2015;36:984-92. 15. Worm SW, Sabin C, Weber R, et al. Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2010;201:318-30. 16. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014;177:292-7. 17. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One 2015;10:e0124653. 18. 楊俊佑, 林素真, 高雅慧. 疼痛解除劑 (如 NSAIDs, tramadol) 臨床應用與健保支付合理性之評估. 2006. 19. Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev 2013;6:Cd006362. 20. Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am J Epidemiol 1981;113:30-43. 21. Eickhoff TC, Sherman IL, Serfling RE. OBservations on excess mortality associated with epidemic influenza. JAMA 1961;176:776-82. 22. Danesh J, Wheeler JG, Hirschfield GM, et al. C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. N Engl J Med 2004;350:1387-97. 23. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26. 24. Baylin A, Hernandez-Diaz S, Siles X, Kabagambe EK, Campos H. Triggers of nonfatal myocardial infarction in Costa Rica: heavy physical exertion, sexual activity, and infection. Ann Epidemiol 2007;17:112-8. 25. Mittleman MA, Mostofsky E. Physical, Psychological and Chemical Triggers of Acute Cardiovascular Events: Preventive Strategies. Circulation 2011;124:346-54. 26. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8. 27. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012;206:1652-9. 28. Hao WR, Lin HW, Chao PZ, et al. Risk of myocardial infarction in patients with rhinosinusitis. Atherosclerosis 2013;226:263-8. 29. Drazen JM. COX-2 inhibitors—a lesson in unexpected problems. N Engl J Med 2005;352:1131-2. 30. US Food and Drug Administration. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk. J Pain Palliat Care Pharmacother 2005;19:83. 31. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8:R153. 32. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013;22:559-70. 33. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086. 34. Coxib and traditional NSAID Trialists’ Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79. 35. US Food and Drug Administration. FDA briefing document on nonsteroidal anti-inflammatory drugs and cardiovascular thrombotic risk. Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management, Advisory Committee, February 10–11, 2014. (Accessed July 6, 2015, at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdf.) 36. Bello A, Holt R. Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications. Drug Saf 2014;37:897-902. 37. Shau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord 2012;12:4. 38. Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010;41:1884-90. 39. Chuang SY, Yu Y, Sheu WH, et al. Association of short-term use of nonsteroidal anti-inflammatory drugs with stroke in patients with hypertension. Stroke 2015;46:996-1003. 40. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164:2472-6. 41. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006;1:297-329. 42. Marsden PA. Inflammation and coagulation in the cardiovascular system: the contribution of influenza. Circ Res 2006;99:1152-3. 43. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000;102:3039-45. 44. Singh BK, Haque SE, Pillai KK. Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity. Expert Opin Drug Metab Toxicol 2014;10:143-56. 45. Gargiulo G, Capodanno D, Longo G, Capranzano P, Tamburino C. Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev Cardiovasc Ther 2014;12:1185-203. 46. Warren-Gash CMJ. The role of influenza and acute respiratory infections as triggers for acute myocardial infarction: UCL (University College London); 2013. 47. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53. 48. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000;21:193-221. 49. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 1997;6 Suppl 3:S51-9. 50. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:50-61. 51. 1992年ICD-9-CM疾病碼一覽表. (Accessed March 4, 2015, at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=18&menu_id=703&webdata_id=1008.) 52. 健保用藥品項104年03月壓縮總檔. (Accessed March 5, 2015, at http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&webdata_id=873.) 53. The Anatomical Therapeutic Chemical (ATC) System and the Defined Daily Dose (DDD). (Accessed Jun 26, 2015, at http://www.whocc.no/.) 54. Marsden-Haug N, Foster VB, Gould PL, Elbert E, Wang H, Pavlin JA. Code-based syndromic surveillance for influenzalike illness by International Classification of Diseases, Ninth Revision. Emerg Infect Dis 2007;13:207-16. 55. Zheng ZJ, Mittleman MA, Tofler GH, et al. Infections prior to acute myocardial infarction onset. J Am Coll Cardiol 1998;31:132-3. 56. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998;351:1467-71. 57. Elkind MS, Carty CL, O'Meara ES, et al. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke 2011;42:1851-6. 58. Luna JM, Kamel H, Willey J, Cheung K, Elkind MS. Influenza-Like Illness is Associated With Risk of Ischemic Stroke: A Case-Crossover Analysis. Stroke 2014;45:ATP163-ATP. 59. Ong C, Lirk P, Tan C, Seymour R. An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 2007;5:19-34. 60. Tramer MR, Williams JE, Carroll D, Wiffen PJ, Moore RA, McQuay HJ. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand 1998;42:71-9. 61. Arora S, Wagner JG, Herbert M. Myth: parenteral ketorolac provides more effective analgesia than oral ibuprofen. Cjem 2007;9:30-2. 62. 李侑珊、簡志誠、陳燕惠、莫世湟、孫維仁. 急診發燒病患使用非類固醇抗發炎注射劑引起過敏性休克:以台灣全民健保資料庫進行回溯性世代研究. 醫療爭議審議報導 2010;44:3-12. 63. Kimmel SE, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiol Drug Saf 2002;11:113-9. 64. 行政院衛生署公告:含Ketorolac成分藥品之注射劑型統一適應症,及口服與注射劑型仿單應加刊警語相關事宜. 2008/04/03. (Accessed July 10, 2015, at http://www.tdrf.org.tw/ch/03_message/mes_02_main.asp?bull_id=3570.) 65. 行政院衛生署公告:含diclofenac成分藥品,統一適應症及仿單標準化相關事宜. 2006/03/06. (Accessed July 10, 2015, at https://www.tdrf.org.tw/ch/03_message/mes_02_main.asp?bull_id=3625.) 66. Label inforamation. (Accessed July 12, 2015, at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.) 67. 全民健康保險藥品給付規定修正規定. 2008/06/11. (Accessed July 10, 2015, at http://site.jah.org.tw/pha/pha_web/c01_news/c01_pdf/Halth/d970611_970012319.pdf.) 68. 不當使用消炎止痛針 增加嚴重藥害風險. 2012/12/13. (Accessed July 10, 2015, at http://www.tdrf.org.tw/ch/02_affair/aff_01_main.asp?bull_id=5001.) 69. 藥害救濟審議案例分享~消炎止痛藥diclofenac. 2014/09/04. (Accessed July 10, 2015, at http://www.tdrf.org.tw/ch/05knows/kno_06_main.asp?bull_id=5575.) 70. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6. 71. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23. 72. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3. 73. van Staa TP, Rietbrock S, Setakis E, Leufkens HG. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 2008;264:481-92. 74. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113:1950-7. 75. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9. 76. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-84. 77. 食品藥物管理局說明非類固醇抗炎藥品(NSAIDs)之用藥安全資訊. 2010/08/20. (Accessed July 10, 2015, at http://www.tmuh.org.tw/tmuh_web/Pharmacy/pdf_medsecurity/99-040.pdf.) 78. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628-36. 79. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007;28:1205-10. 80. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008;29:96-103. 81. Pesonen E, Andsberg E, Grubb A, et al. Elevated infection parameters and infection symptoms predict an acute coronary event. Ther Adv Cardiovasc Dis 2008;2:419-24. 82. Guan X, Yang W, Sun X, et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflamm Res 2012;61:591-8. 83. Warren-Gash C, Geretti AM, Hamilton G, Rakhit RD, Smeeth L, Hayward AC. Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: a case-control study. BMJ Open 2013;3. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51804 | - |
dc.description.abstract | 研究背景
過去研究指出急性呼吸道感染會誘發急性心肌梗塞的發生,而非類固醇消炎止痛藥(nonsteroidal anti-inflammatory drugs, NSAIDs)亦會增加急性心肌梗塞發生的風險。臨床上醫師常處方NSAIDs藥品以緩解急性呼吸道感染病人相關症狀,不過目前沒有任何文獻同時探討此二因子之結合性效應對急性心肌梗塞風險的影響。 研究目的 利用全民健康保險資料庫探討急性呼吸道感染與NSAIDs的使用對首次急性心肌梗塞的發生之結合性效應。 研究材料與方法 本研究為一病例交叉研究,以全民健康保險研究資料庫中2000、2005、2010年三個承保抽樣歸人檔(涵蓋人口約300萬人)為資料來源,選取2000-2011年間首次因急性心肌梗塞住院的病人做為病例,定義因急性心肌梗塞住院的日期為急性心肌梗塞發生日(index date),選取index date前1-7天為病例期(case period),index date前366-372天為對照期(control period),比較病例期與對照期中4種暴露情形(只有急性呼吸道感染、只有NSAIDs的使用、同時有此二暴露、完全沒有此二暴露)是否有差異。資料分析利用mutivariable conditional logistic regression進行勝算比(OR)的預測並校正病例期與對照期不一致的共病症與不一致的併用藥品。 研究結果 本研究共分析3,019位首次急性心肌梗塞的病人。結果顯示在病例期同時有急性呼吸道感染及使用NSAIDs的病人、只有急性呼吸道感染的病人、只有使用NSAIDs的病人都較對照期多,在校正病例期與對照期不一致的共病症與不一致的併用藥品後,分別會增加4.78倍(95% CI: 3.32-6.89)、2.85倍(95% CI: 2.15-3.77)及1.61倍(95% CI: 1.33-1.95)急性心肌梗塞發生的風險。在次族群分析中,發現當有急性呼吸道感染時,使用注射劑型的NSAIDs、propionic acid derivatives類的NSAIDs及高劑量的NSAIDs風險較高。 結論 本研究發現急性呼吸道感染與NSAIDs使用對急性心肌梗塞風險具有結合性效應,在有急性呼吸道感染的情況下,NSAIDs的使用會使得急性心肌梗塞風險提高,尤其是注射劑型的NSAIDs。 | zh_TW |
dc.description.abstract | Background
Previous studies showed that acute respiratory infection would trigger acute myocardial infarction and use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of acute myocardial infarction. In clinical practice, physicians usually prescribed NSAIDs for patients with acute respiratory infection to relieve symptoms. However, there is lack of studies focusing on the association between risk of acute myocardial infarction and NSAIDs use during acute respiratory infection. Objective To investigate the joint effect of acute respiratory infection and use of NSAIDs on risk of acute myocardial infarction by using the National Health Insurance Research Database in Taiwan. Materials and Methods We conducted a retrospective case-crossover study by using three sets of longitudinal health insurance database (LHID 2000, 2005, 2010) from Taiwan’s National Health Insurance Research Database. All patients who were first hospitalized due to acute myocardial infarction during 2000-2011 were enrolled for analysis. The date of first admission for acute myocardial infarction was defined as index date. The 1-7 days and 366-372 days prior to index date were defined as case and matched control period for each patient. We compared the following exposure status between case and control periods: acute respiratory infection without NSAIDs use, NSAIDs use without acute respiratory infection, both acute respiratory infection and NSAIDs use, neither acute respiratory infection nor NSAIDs use. Multivariable conditional regression models were used to estimate odds ratios adjusting discordant diagnoses of comorbidities and discordant use of concomitant medications. Results There were 3,019 newly diagnosed AMI hospitalized patients fulfilled the study criteria. In general, the risk of acute myocardial infarction is the highest in patients with acute respiratory infection and NSAIDs use (OR: 4.78, 95% CI: 3.32-6.89), and subsequently the odds ratios in patients with acute respiratory infection only and in patients with NSAIDs use only are 2.85 (95% CI: 2.15-3.77) and 1.61 (95% CI: 1.33-1.95), respectively. We found that parenteral NSAIDs, propionic acid derivatives of NSAIDs and high dose NSAIDs were associated with higher risk of acute myocardial infarction in patients with acute respiratory infection. Conclusions There was joint effect of acute respiratory infection and use of NSAIDs on risk of acute myocardial infarction. NSAIDs use was associated with increased risk of acute myocardial infarction in patients with acute respiratory infection, especially parenteral NSAIDs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:50:42Z (GMT). No. of bitstreams: 1 ntu-104-R02451006-1.pdf: 998938 bytes, checksum: 5ae8f960b9bacbe098d3355af9e920ee (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iv 目錄 vi 表目錄 ix 圖目錄 x 縮寫表 xi 第1章 前言 1 第2章 文獻回顧 2 2.1 急性呼吸道感染對急性心肌梗塞風險的文獻回顧 2 2.2 NSAIDs藥品對急性心肌梗塞風險的文獻回顧 3 2.3 急性呼吸道感染與使用NSAIDs藥品對急性心肌梗塞風險的文獻回顧 5 2.4 急性呼吸道感染與使用NSAIDs藥品引發急性心肌梗塞的可能機轉 5 2.5 採用病例交叉設計的優缺點 6 第3章 研究目的 8 3.1 研究動機 8 3.2 研究目的 8 第4章 研究方法 9 4.1 研究設計 9 4.2 資料來源 9 4.2.1 ATC code系統與分類原則 10 4.2.2 DDD的定義與使用原則 10 4.3 研究對象 11 4.3.1 病例(Case)定義 11 4.3.2 篩選研究對象流程 11 4.4 定義急性呼吸道感染之暴露 11 4.5 定義NSAIDs藥品暴露與劑量計算 12 4.5.1 定義每張處方箋的使用期間 12 4.5.2 定義每個時間窗內NSAIDs暴露資料 12 4.5.3 計算每個時間窗內NSAIDs的累積劑量 12 4.5.4 計算每個時間窗內NSAIDs的最大當日劑量 13 4.6 定義同時有急性吸道感染與NSAIDs暴露的情況 13 4.7 變項定義 13 4.7.1 依變項 13 4.7.2 自變項 13 4.7.3 控制變項 14 4.8 統計分析 14 4.8.1 作業軟體 14 4.8.2 統計模型設定 14 4.8.3 描述性分析 14 4.8.4 相關性分析 14 4.9 敏感性分析 15 第5章 研究結果 16 5.1 研究族群背景資料 16 5.1.1 研究族群基本特性 16 5.1.2 研究族群於病例期與對照期的共病症分布情形 16 5.1.3 研究族群於病例期與對照期的藥品使用情形 16 5.1.4 研究族群於病例期與對照期的NSAIDs藥品使用情形 17 5.2 急性呼吸道感染及(或)NSAIDs使用與急性心肌梗塞風險 17 5.3 急性呼吸道感染及(或) NSAIDs使用途徑與急性心肌梗塞風險 18 5.4 急性呼吸道感染及(或)NSAIDs種類與急性心肌梗塞風險 18 5.5 急性呼吸道感染及(或)NSAIDs劑量與急性心肌梗塞風險 19 5.5.1 時間窗內NSAIDs的累積劑量 19 5.5.2 時間窗內NSAIDs的最大當日劑量 19 5.6 敏感性分析 20 第6章 討論 21 6.1 研究族群的特性與藥品之使用 21 6.2 急性呼吸道感染及(或)NSAIDs使用與急性心肌梗塞風險 21 6.2.1 急性呼吸道感染與急性心肌梗塞風險之相關性 22 6.2.2 NSAIDs使用與急性心肌梗塞風險之相關性 23 6.3 急性呼吸道感染及(或)NSAIDs使用途徑與急性心肌梗塞風險 24 6.4 急性呼吸道感染及(或)NSAIDs種類與急性心肌梗塞風險 26 6.5 急性呼吸道感染及(或)NSAIDs劑量與急性心肌梗塞風險 27 6.6 研究特色與限制 28 6.6.1 研究特色與優點 28 6.6.2 研究限制 28 第7章 結論與建議 30 表 31 圖 51 參考文獻 55 | |
dc.language.iso | zh-TW | |
dc.title | 急性呼吸道感染與使用非類固醇消炎止痛藥對急性心肌梗塞發生風險的結合性效應:病例交叉研究 | zh_TW |
dc.title | Joint Effect of Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Risk of Acute Myocardial Infarction:A Case-Crossover Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭斐元(Fei-Yuan Hsiao) | |
dc.contributor.oralexamcommittee | 陳建煒(K. Arnold Chan),方震中(Cheng-Chung Fang) | |
dc.subject.keyword | 急性心肌梗塞,急性呼吸道感染,非類固醇消炎止痛藥(NSAIDs),病例交叉研究,全民健保資料庫, | zh_TW |
dc.subject.keyword | acute myocardial infarction,acute respiratory infection,nonsteroidal anti-inflammatory drugs(NSAIDs),case-crossover study,National Health Insurance Research Database(NHIRD), | en |
dc.relation.page | 59 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-10-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 975.53 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。